Dr. Lawrence H. Einhorn will continue his studies in Clinical Cancer Research through the Outstanding Investigator Grant. Pivotal studies will continue to be done in patients with testicular cancer. Dr. Einhorn and co-investigators will evaluate a new aggressive five drug regimen as initial therapy for patients with advanced testicular cancer. New and innovative approaches for salvage therapy of testicular cancer will also be carefully studied. In addition, correlatives clinical studies will be done evaluating antiemetics and hematopoietic growth factors. In addition, Dr. Einhorn and colleagues will continue to participate in clinical trials for common malignancies such as colorectal cancer, lung cancer, breast cancer, etc. Recognizing the importance of these trials and the frequent necessity to perform them at the community level, Dr. Einhorn helped form the consortium of community oncologist in Indiana and surrounding areas called the Hoosier Oncology Group. Indiana University is a research base for this organization and Dr. Einhorn is the Chief Scientific Officer. One of the exciting new areas of interest has been the development of a new protocol in metastatic bladder cancer. This phase II study will evaluate the combination of vinblastine + ifosfamide + gallium in patients with metastatic bladder cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Unknown (R35)
Project #
5R35CA039844-09
Application #
3479211
Study Section
Special Emphasis Panel (SRC (88))
Project Start
1985-07-01
Project End
1999-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
9
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Loehrer Sr, Patrick J; Wang, Wei; Johnson, David H et al. (2004) Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 22:293-9
Kurup, Anupama; Loehrer Sr, Patrick J (2004) Thymoma and thymic carcinoma: therapeutic approaches. Clin Lung Cancer 6:28-32
Kesler, Kenneth A; Wright, Cameron D; Loehrer Sr, Patrick J (2004) Thymoma: current medical and surgical management. Semin Neurol 24:63-73
Ganjoo, K N; Rieger, K M; Kesler, K A et al. (2000) Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors. Cancer 88:1051-6
Sweeney, C J; Hermans, B P; Heilman, D K et al. (2000) Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer. J Clin Oncol 18:358-62
Miller, D K; Munshi, N; Loesch, D et al. (2000) A phase II trial of high dose epirubicin in patients with advanced breast carcinoma. Cancer 88:375-80
Sonpavde, G; Ansari, R; Walker, P et al. (2000) Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol 23:68-70
Behnia, M; Foster, R; Einhorn, L H et al. (2000) Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. Eur J Cancer 36:472-5
Thomas, C R; Wright, C D; Loehrer, P J (1999) Thymoma: state of the art. J Clin Oncol 17:2280-9
Ng, E W; Porcu, P; Loehrer Sr, P J (1999) Sacrococcygeal teratoma in adults: case reports and a review of the literature. Cancer 86:1198-202

Showing the most recent 10 out of 109 publications